on DBV TECHNOLOGIES (EPA:DBV)
DBV Technologies Adjusts Attendance at Global Conference
DBV Technologies, a biopharmaceutical company focused on food allergies, has updated its plans for the Goldman Sachs 47th Annual Global Healthcare Conference. Originally scheduled for a fireside chat, CEO Daniel Tassé will now only participate in investor meetings on June 9, 2026, in Miami, FL, due to an unavoidable travel issue.
DBV Technologies, traded on Euronext and Nasdaq, specializes in non-invasive treatments for food allergies through its VIASKIN patch technology. This technology is part of epicutaneous immunotherapy (EPIT), aiming to desensitize individuals to allergens by leveraging immune properties of the skin. The company continues its clinical trials focused on peanut allergies in young populations.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all DBV TECHNOLOGIES news